Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech, Biogen Receive Complete Response From FDA For Rituxan
Genentech, a wholly-owned member of the Roche Group and Biogen Idec have received a complete response from the FDA for a supplemental Biologics License Application (sBLA) for Rituxan
Genentech, a wholly-owned member of the Roche Group and Biogen Idec have received a complete response from the FDA for a supplemental Biologics License Application (sBLA) for Rituxan
UCB has reported that Cimzia (certolizumab pegol), together with methotrexate (MTX), has showed sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early
Forest Laboratories and Cypress Bioscience have reported that Savella (milnacipran HCI) 100 mg/day (50 mg twice daily) demonstrated statistically significant and clinically meaningful concurrent improvements in pain, patient
Roche has presented the results of a two-year data from the Lithe study at the American College of Rheumatology (ACR). Reportedly, with long-term use, patients with rheumatoid arthritis
Data presented at the 73rd annual scientific meeting of the American College of Rheumatology highlight effects of baseline characteristics on achievement of serum uric acid (sUA) levels to
GlaxoSmithKline (GSK) has received approval for Cervarix in Japan, which becomes the first cervical cancer vaccine to be approved by the Japanese Ministry of Health, Labour and Welfare
As part of an investigator-initiated five patient pilot study in Japan, Cytori was informed that stem and regenerative cells from a patient’s own fat tissue were used to
The FDA has approved AstraZeneca’s Crestor (rosuvastatin calcium) for use in children between 10-17 ages with heterozygous familial hypercholesterolemia (HeFH) when diet therapy fails to reduce elevated cholesterol.
Highlights: Earnings per diluted share in the third quarter of 2009 increased to $0.50 from $0.15 per diluted share in the same period of the prior year, an
Alios BioPharma has bagged US Patent No. 7,597,884 from US Patent and Trademark Office (USPTO). The company has claimed that numerous compounds from its glycoengineering program including its